Artelo Biosciences annual stock-based compensation
2017
2018
2019
2020
2021
2022
2023
2024
2025
Artelo Biosciences Stock-Based Compensation Growth & History (ARTL)
Artelo Biosciences's stock-based compensation was $1.1M for fiscal 2025.
View full Artelo Biosciences company overviewArtelo Biosciences annual stock-based compensation history
| Fiscal year | Period ended | Stock-based compensation | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $1.1M | $324,000 | +39.61% |
| 2024 | 2024-12-31 | $818,000 | −$202,000 | −19.80% |
| 2023 | 2023-12-31 | $1.0M | −$1.4M | −58.50% |
| 2022 | 2022-12-31 | $2.5M | — | — |
| 2021 | 2021-08-31 | $1.5M | $1.1M | +301.84% |
| 2020 | 2020-08-31 | $381,000 | −$44,110 | −10.38% |
| 2019 | 2019-08-31 | $425,110 | $135,106 | +46.59% |
| 2018 | 2018-08-31 | $290,004 | $286,672 | +8603.60% |
| 2017 | 2017-08-31 | $3,332 | — | — |
Artelo Biosciences quarterly stock-based compensation
Q3.17
Q1.18
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q2.21
Q3.21
Q3.21
Q3.21
Q1.22
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Stock-based compensation | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $570,000 | $420,000 | +280.00% |
| Q1 2026 | 2026-03-31 | $401,000 | $209,000 | +108.85% |
| Q4 2025 | 2025-12-31 | $368,000 | $167,000 | +83.08% |
| Q3 2025 | 2025-09-30 | $432,000 | $223,000 | +106.70% |
| Q2 2025 | 2025-06-30 | $150,000 | −$45,000 | −23.08% |
| Q1 2025 | 2025-03-31 | $192,000 | −$21,000 | −9.86% |
| Q4 2024 | 2024-12-31 | $201,000 | −$18,000 | −8.22% |
| Q3 2024 | 2024-09-30 | $209,000 | −$13,000 | −5.86% |
| Q2 2024 | 2024-06-30 | $195,000 | −$30,000 | −13.33% |
| Q1 2024 | 2024-03-31 | $213,000 | −$141,000 | −39.83% |
| Q4 2023 | 2023-12-31 | $219,000 | −$389,000 | −63.98% |
| Q3 2023 | 2023-09-30 | $222,000 | −$385,000 | −63.43% |
| Q2 2023 | 2023-06-30 | $225,000 | −$394,000 | −63.65% |
| Q1 2023 | 2023-03-31 | $354,000 | −$270,000 | −43.27% |
| Q4 2022 | 2022-12-31 | $608,000 | — | — |
| Q3 2022 | 2022-09-30 | $607,000 | $105,000 | +20.92% |
| Q2 2022 | 2022-06-30 | $619,000 | $10,000 | +1.64% |
| Q1 2022 · Mar 31 | 2022-03-31 | $624,000 | $105,000 | +20.23% |
| Q1 2022 · Nov 30 | 2021-11-30 | $571,000 | $520,000 | +1019.61% |
| Q3 2021 · Sep 30 | 2021-09-30 | $502,000 | — | — |
| Q3 2021 · Jun 30 | 2021-06-30 | $609,000 | — | — |
| Q3 2021 · May 31 | 2021-05-31 | $618,358 | $565,376 | +1067.11% |
| Q2 2021 · Mar 31 | 2021-03-31 | $519,000 | — | — |
| Q2 2021 · Feb 28 | 2021-02-28 | $341,817 | $236,420 | +224.31% |
| Q1 2021 | 2020-11-30 | $51,000 | −$117,019 | −69.65% |
| Q4 2020 | 2020-08-31 | $54,602 | $5,587 | +11.40% |
| Q3 2020 | 2020-05-31 | $52,982 | −$239,758 | −81.90% |
| Q2 2020 | 2020-02-29 | $105,397 | $63,093 | +149.14% |
| Q1 2020 | 2019-11-30 | $168,019 | $126,968 | +309.29% |
| Q4 2019 | 2019-08-31 | $49,015 | −$72,238 | −59.58% |
| Q3 2019 | 2019-05-31 | $292,740 | $279,990 | +2196.00% |
| Q2 2019 | 2019-02-28 | $42,304 | −$96,446 | −69.51% |
| Q1 2019 | 2018-11-30 | $41,051 | $23,800 | +137.96% |
| Q4 2018 | 2018-08-31 | $121,253 | — | — |
| Q3 2018 | 2018-05-31 | $12,750 | $11,084 | +665.31% |
| Q2 2018 | 2018-02-28 | $138,750 | — | — |
| Q1 2018 | 2017-11-30 | $17,251 | — | — |
| Q3 2017 | 2017-05-31 | $1,666 | — | — |
Artelo Biosciences stock-based compensation trends
Between the periods ended 2017-08-31 and 2025-12-31, Artelo Biosciences's stock-based compensation increased from $3,332 to $1.1M, a change of $1.1M. The latest reported quarter, Q2 2026, shows $570,000.
About the metric
What stock-based compensation means
Stock-based compensation is the expense associated with equity awards such as restricted stock and employee options. It is a non-cash expense when recognized, but it can dilute existing shareholders unless offset by share repurchases.
Calculation and source
SEC-reported stock-based compensation
TickerStat standardizes share-based compensation reported in company SEC filings. The history shows recognized compensation expense or its cash-flow-statement adjustment, not the grant-date value of new awards or a forecast of future dilution. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Artelo Biosciences source filings ↗